Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.
Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...
The near-term pipeline for COPD has several ICS, LABA and LAMA combinations in development with claims of improved efficacy and better safety profiles. Moreover, the development of more innovative ...
In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...
At the moment, the recommended treatment for COPD in Europe is an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA), or LABA/LAMA dual ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...
The Spanish COPD guidelines recommend treatment of the ... to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more severe cases, theophylline or roflumilast may ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback